New Data on AtheroGenics AGI-1067 Accepted for Presentation at the European Society of Cardiology Congress 2007
ATLANTA, GA – August 29, 2007 – AtheroGenics, Inc. (Nasdaq: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that new scientific data of its oral antidiabetic agent AGI-1067 has been accepted for an oral presentation in a Hotline & Clinical Trial Updates session at the upcoming European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria.
The presentation is titled, “The effect of the novel anti-oxidant AGI-1067 (succinobucol) on glycemic control, new onset diabetes and clinical events in patients with a recent acute coronary syndrome: the Aggressive Reduction of Inflammation Stops Events study (ARISE).” It will be presented on Wednesday, September 5, 2007, by Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine, Harvard Medical School; Senior Physician in Cardiology at Brigham and Women's Hospital and co-principal investigator of the ARISE clinical trial.
Additional information regarding the ESC Congress 2007 can be accessed at http://www.escardio.org.
About AGI-1067
AGI-1067 has demonstrated efficacy in over 2,200 diabetic subjects showing improvements in glycemic control. This effect with AGI-1067 has been confirmed in other clinical and preclinical studies. Oxidative stress and inflammation have been demonstrated to play a central role in the pathogenesis of insulin resistance and diabetes. AGI-1067 is an anti-inflammatory antioxidant agent that works by inhibiting signaling pathways that are activated in response to oxidative stress and pro-inflammatory stimuli.
AGI-1067 has been evaluated in numerous pre-clinical and clinical studies, including a recent cardiovascular clinical outcomes study comprised of 6,144 subjects followed for up to three years. In that study, AGI-1067 achieved significant results in important pre-specified diabetes endpoints, demonstrating an improvement in glycemic control in patients with diabetes already being managed by conventional therapies. In addition, the number of study subjects who developed diabetes for the first time was reduced by more than 60 percent.
Posted: August 2007
